Literature DB >> 11358917

A political analysis of corporate drug donations: the example of Malarone in Kenya.

R Shretta1, G Walt, R Brugha, R Snow.   

Abstract

This paper describes the introduction of the Malarone Donation Programme in KENYA: Using a policy analysis approach it illustrates the political nature of donation programmes and how they are affected by a large and varied group of national, regional and international stakeholders, with different levels of influence and experience. The paper shows that interaction between these different groups may affect the development and implementation of the donation programme. It ends by raising some more general questions about public/private partnerships and corporate donation programmes, and their potential impact on national drug policies.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11358917     DOI: 10.1093/heapol/16.2.161

Source DB:  PubMed          Journal:  Health Policy Plan        ISSN: 0268-1080            Impact factor:   3.344


  7 in total

1.  A global health fund: a leap of faith?

Authors:  R Brugha; G Walt
Journal:  BMJ       Date:  2001-07-21

Review 2.  Atovaquone-proguanil for treating uncomplicated malaria.

Authors:  A Osei-Akoto; L Orton; S P O Owusu-Ofori
Journal:  Cochrane Database Syst Rev       Date:  2005-10-19

3.  Importance of strategic management in the implementation of private medicine retailer programmes: case studies from three districts in Kenya.

Authors:  Timothy Abuya; Abdinasir Amin; Sassy Molyneux; Willis Akhwale; Vicki Marsh; Lucy Gilson
Journal:  BMC Health Serv Res       Date:  2010-07-02       Impact factor: 2.655

4.  Are drug companies living up to their human rights responsibilities? Moving toward assessment.

Authors:  Sofia Gruskin; Zyde Raad
Journal:  PLoS Med       Date:  2010-09-28       Impact factor: 11.069

5.  Can policy analysis theories predict and inform policy change? Reflections on the battle for legal abortion in Indonesia.

Authors:  Claudia Surjadjaja; Susannah H Mayhew
Journal:  Health Policy Plan       Date:  2010-12-22       Impact factor: 3.344

6.  Public-private partnerships to build human capacity in low income countries: findings from the Pfizer program.

Authors:  Taryn Vian; Sarah C Richards; Kelly McCoy; Patrick Connelly; Frank Feeley
Journal:  Hum Resour Health       Date:  2007-03-02

7.  Clinical development of new prophylactic antimalarial drugs after the 5th Amendment to the Declaration of Helsinki.

Authors:  Geoffrey S Dow; Alan J Magill; Colin Ohrt
Journal:  Ther Clin Risk Manag       Date:  2008-08       Impact factor: 2.423

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.